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prove important in revealing the roles of aggrecanase versus 
MMP aggrecanolysis in the IGD of aggrecan at different stages 
of human OA. 
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INCREASED SYNOVIAL FLUID AND DECREASED 
SERUM BONE ALKALINE PHOSPHATASE 
CONCENTRATIONS ASSOCIATED WITH EQUINE 
OSTEOCHONDRAL FRAGMENTATION 
TN Trumble, MP Brown, KA Merritt 
Large Animal Clinical Sciences, University of Florida, 
Gainesville, FL 
Aim of study: To determine the bone alkaline phosphatase 
(BAP) concentrations in the synovial fluid and serum from horses 
with osteochondral fragmentation compared to normal, treadmill- 
exercised horses. 
Methods: Synovial fluid was collected from the carpal joints and 
blood was collected from the jugular vein of 9 mature Thorough- 
bred horses presented for arthroscopic debridement of osteo- 
chondral fragmentation. As a comparable xercise control group, 
serum and carpal synovial fluid samples were collected from 
14 mature Thoroughbred horses after 6 weeks of regular tread- 
mill training. BAP concentrations were measured in the synovial 
fluid and serum using a commercially available immunoassay 
(Metra TM BAP, Quidel Corporation, San Diego, CA). Synovial fluid 
and serum were compared between the osteochondral fragment 
group of horses and the exercise control group using an unpaired 
t-test. A value of P<0.05 was considered significant. 
Results: The synovial fluid BAP concentration was significantly 
elevated (P<0.01) in the horses with osteochondral fragments 
(mean 4- standard deviation, 21.87 4- 8.4 U) compared to the ex- 
ercise control horses (13.32 4- 6.44 U). However, the serum BAP 
concentration was significantly lower (P<0.001) in the horses 
with osteochondral fragments (31.45 4- 8.44 U) compared to the 
exercise control horses (52.33 4- 11.64 U). 
Conclusions: The elevated concentrations of BAP in the syn- 
ovial fluid of horses with osteochondral fragments compared to 
exercise control horses may be due to local production and re- 
lease of the enzyme from the exposed subchondral bone and 
inflamed synovium. In addition, delayed clearance of BAP from 
the joint as a result of joint effusion may also result in greater 
synovial fluid concentrations. The lower concentrations of BAP in 
the serum of horses with osteochondral fragmentation compared 
to exercise control horses may be due to the basic physiologic re- 
sponse of bone to exercise compared to injury. In the uninjured, 
exercised horse, bone formation (modeling) predominates to ad- 
just to the loads applied during exercise. However, when acute in- 
jury to the bone occurs, as with osteochondral fragmentation, the 
bone may go through a remodeling process. If so, the bone must 
first go through a resorptive period before the osteoblasts would 
be recruited to the site to initiate new bone formation. Therefore, 
due to this relatively delayed response of the osteoblasts, the 
serum BAP concentrations may be lower in the osteochondral 
fragmentation horses compared to horses with exercise-induced 
modeling. Examination of both the synovial fluid and serum BAP 
concentrations in various types of joint disease is valuable in de- 
termining the different local and systemic effects that occur in re- 
sponse to the joint disease. 
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The ability to quantitate aggrecan fragments and their neoepi- 
topes in both plasma and synovial fluids is important for the devel- 
opment of biomarkers that will monitor aggrecan degradation in 
osteoarthritis. While the ultimate goal of these biomarker efforts is 
the development of high sensitivity, reproducible assays capable 
of evaluating large number of clinical and preclinical samples, it is 
essential that these results can be independently validated using 
different echnology to insure the specificity of the immunoassays 
under development. Accordingly, the present study has focused 
on the detection of aggrecan fragments by Western blot analysis 
using two color infrared imaging technology. Initial studies have 
focused on the detection of a 32 amino acid peptide fragment (32- 
mer) following aggrecan digestion with matrix metalloprotease 13 
and ADAMTS 4/5. A rabbit affinity purified polyclonal with recog- 
nition of the carboxy terminus and a mouse monoclonal recogniz- 
ing the amino terminus of the peptide were used to detect the 32- 
mer by Western blot analysis following SDS gel electrophoresis 
of the aggrecan digests. The fluorochrome conjugated detection 
antibodies (anti rabbit and anti mouse) were chosen based on the 
780 and 680 excitation wavelengths of the Odyssey's two diode 
lasers. This technology insures the specificity of the antibodies 
used for higher throughput assays by requiring co-staining with 
both antibodies to the aggrecan peptide of interest and is eas- 
ily visualized in the same sample lane. The ability to utilize this 
approach in complex biologic matrices will provide a greater un- 
derstanding of both neoepitope levels as well as the potential size 
diversity of the neoepitope containing aggrecan fragments in both 
clinical and preclinical samples. 
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The cleavage of aggrecan by aggrecanases (e.g. ADAMTS-4/5) 
generates a series of neoepitope xposed fragments which are 
thought to be potential candidates for Osteoarthritis (OA) asso- 
ciated biomarkers. The ability to detect these neoepitope frag- 
ments in patient samples could potentially aid physicians and re- 
searchers in providing additional criteria in conjunction with clin- 
ical signs for selecting the most appropriate and effective treat- 
ments for symptom amelioration or disease modification. In the 
present study, a series of competitive nzyme-linked immunoab- 
sorbent assays (ELISAs) have been developed to quantitate OA 
biological samples for the most abundant neoepitope fragments 
using affinity purified rabbit polyclonal antibodies (poABs) de- 
rived following synthetic peptide immunizations. These antibod- 
ies were characterized by BIACORE analysis with KD values for 
the specific neoepitope sequences between 10-1° to 10-8M. In 
the competitive ELISA format, the assay measures the ability of 
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these poABs to compete for the binding of fluid phase neoepitope 
fragments with solid phase ovalbumin linked synthetic peptides. 
The solid phase complex is detected with peroxidase conjugated 
anti-rabbit IgG. These competitive ELISAs have nM sensitivity as 
determined by spike recovery of synthetic peptide in the assay 
buffer. Neoepitope specific ELISA assays will enable the quanti- 
tative evaluation of neoepitope containing aggrecan fragments in 
response to disease progression and therapeutic intervention. 
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W Zeng 1 , LA Collins-Racie 2, SS Glasson 1 , T Blanchet 1 , HL 
Ma 1 , B Hopkins 1 , KE Georgiadis 1, ER LaVallie 2, EA Morris 1 , 
CR Flannery 1 
1 Women's Health & Musculoskeletal Biology, Wyeth Research, 
Cambridge, MA; 2Biological Technologies, Wyeth Research, 
Cambridge, MA 
Aim: To measure the levels of aggrecanase (ADAMTS)- 
generated aggrecan AGG-C1 neoepitope (G1-TEGE 373) in bio- 
logical fluids from a preclinical model of osteoarthritis (OA), and 
determine its utility as a correlative biomarker for disease pro- 
gression. 
Methods: A preclinical model of OA was propagated following 
anterior cruciate ligament ransection (ACLT) in rabbit hind-limbs, 
and biological fluid samples (i.e. serum, synovial fluid, urine) were 
collected at various time points post-surgery. Samples from age- 
matched control (unoperated) animals were similarly harvested. 
Monoclonal antibody AGG-C1 (which specifically recognizes the 
aggrecanase-generated catabolic neoepitope ... TEGE 373) was 
utilized in a competitive ELISA format to assay biological fluids. 
Results: AGG-C1 neoepitope was readily detectable in synovial 
fluid and serum samples, wherein its levels were elevated longi- 
tudinally following ACLT surgery. 
Conclusions: During the course of degenerative joint diseases 
such as OA, ADAMTS (aggrecanase)-mediated aggrecanoly- 
sis contributes ignificantly to cartilage proteoglycan depletion, 
and ultimate tissue destruction. Specifically, cleavage of the 
aggrecanase-susceptible E373-A 374 bond within the interglobular 
domain causes the detrimental loss of sGAG-rich aggrecan frag- 
ments, thereby compromising the biomechanical competence of 
the articular cartilage. Concordantly, aggrecanase-generated G1
domains (G1-TEGE 373) are also released from cartilage into the 
synovial fluid. In the present study, we have demonstrated the 
utility of neoepitope-specific monoclonal antibody AGG-C1 (anti- 
TEGE 373) in a preclinical biomarker assay for OA progression, us- 
ing accessible biological fluids such as peripheral blood (serum), 
wherein the AGG-C1 neoepitope persists. 
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Aim: ADAMTS-4 and ADAMTS-5 are known to cleave aggre- 
can, the major articular cartilage proteoglycan, at various sites 
along the molecule. This results in the release of aggrecan frag- 
ments into synovial fluid which contain the aggrecan neoepi- 
tope NITEGE and the glycosaminoglycan, chondroitin sulphate 
(CS). We have used this information to develop two pharmaco- 
dynamic assays to test ADAMTS-4/5 inhibitors in vivo. Aggrecan 
degradation is induced by the intra-articular injection of recom- 
binant ADAMTS-4 or ADAMTS-5 followed by detection of aggre- 
can catabolism with either a direct ELISA based on an antibody 
to a CS epitope or a sandwich ELISA utilizing antibodies to both 
the NITEGE neoepitope and the HABR (aggrecan hyaluronic acid 
binding region). 
Method: Male Lewis rats are anaesthetized and injected intra- 
articularly with varying concentrations of either recombinant 
ADAMTS-4 or ADAMTS-5 dissolved in 50ul of buffer. The con- 
tralateral knee is injected with buffer alone as a control. One 
hour after injection of enzyme the knees are lavaged with 200ul 
of saline and the synovial lavage assayed for CS and NITEGE 
content. Lavage fluid is measured for CS by an ELISA which 
uses mouse monoclonal antibody CS56 that recognizes CS and 
for NITEGE with a sandwich ELISA which uses antibodies to 
hyaluronic binding region (HABR) of aggrecan and the NITEGE 
neoepitope. MMP-13 (2.5ug per knee) was used as a specificity 
control for the NITEGE-HABR ELISA. 
To test ADAMTS-4/5 inhibitory activity of com pounds in this assay 
we used two broad-spectrum MMP inhibitors (Marimastat, British 
Biotech and Ro130830, Roche Bioscience) that also have some 
activity against ADAMTS-4 and ADAMTS-5: Marimastat IC50 22 
nM and 80 nM; Ro 130830 Marimastat IC50 200 nM and 56 nM 
respectively. IC50's were determined from an alpha screen assay 
for aggrecanases using a synthetic 43mer peptide as substrate. 
The compounds were dosed at 50mg/kg po one hour before in- 
jection of enzyme. Plasma was taken one hour after enzyme in- 
jection and assayed for MMP activity to confirm the presence of 
compound. 
Results: Both ADAMTS-4 and ADAMTS-5 at 10ug per knee were 
able to degrade rat knee cartilage aggrecan in vivo as measured 
by the release of CS and the NITEGE neoepitope. Levels of CS 
and NITEGE in synovial lavage were at least 10 fold higher than 
those seen with buffer alone. No NITEGE fragments were de- 
tected in MMP-13 injected knees. 
Marimastat was the most potent compound at inhibiting 
ADAMTS-4 (CS ELISA 60% and NITEGE-HABR ELISA 70%) 
and Ro130830 most potent for ADAMTS-5 (CS ELISA 60% and 
NITEGE-HABR ELISA 60%). The plasma assay for MMP activity 
showed complete inhibition of enzymatic activity. 
Discussion: Both ADAMTS-4 and ADAMTS-5 were able to de- 
grade aggrecan after intra-articular injection as measured by 
chondrotin sulphate and NITEGE-HABR ELISAs. This degrada- 
tion of aggrecan can be inhibited by reference compounds con- 
firming we have a pharmacodynamic assay for testing potential 
ADAMTS-4/5 inhibitors in vivo. 
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PROMOTER 
Z Fan 1 , G Tardif 1 , C Boileau 1 , D Hum 1 , A Watson 1 , J Bidwell 2, 
C Geng 1 , JP Pelletier 1, J MarteI-Pelletier 1 
10steoarthritis Research Unit, University of Montreal Hospital 
Centre, Notre Dame Hospital, Montreal, QC, Canada; 
2Department of Anatomy & Cell Biology, Indiana University 
School of Medicine, Indianapolis, IN 
Aim of Study: The human MMP-13 plays a major role in normal 
cartilage remodeling and osteoarthritic (OA) processes. We pre- 
viously identified the regulatory site AGRE (GAAAA GAAAAAG) 
in the proximal promoter of this gene. Electrophoretic mobility 
shift assays (EMSA) done with nuclear extracts from OA chon- 
drocytes showed the presence of two AGRE-protein binding com- 
plexes, which depended on the pathophysiological state of the 
cells. In this study, we further investigated whether each AGRE 
